{"id":390564,"date":"2018-10-26T00:00:00","date_gmt":"2018-10-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0007-2018-biopharma-rheumatoid-arthritis-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-03-31T10:47:49","modified_gmt":"2026-03-31T10:47:49","slug":"dlsfim0007-2018-biopharma-rheumatoid-arthritis-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0007-2018-biopharma-rheumatoid-arthritis-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Rheumatoid Arthritis | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The mature rheumatoid arthritis (<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1) inhibitors Enbrel (Amgen), Humira (AbbVie), and Remicade (Janssen); five non-<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 biologics, including the recently approved\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-6 inhibitor Kevzara; and\u00a0oral\u00a0<abbr data-original-title=\"Janus activated kinase\" title=\"\">Jak<\/abbr>\u00a0inhibitors Xeljanz\u00a0(Pfizer) and recently approved Olumiant (Eli Lilly). The\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors are the most widely prescribed biologics for\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>\u00a0patients refractory to conventional\u00a0<abbr data-original-title=\"disease-modifying antirheumatic drug\" title=\"\">DMARD<\/abbr>s, and the non-<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 biologics and\u00a0<abbr data-original-title=\"Janus activated kinase\" title=\"\">Jak<\/abbr>inhibitors\u00a0largely compete for use in\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-refractory patients. However, the premium-priced branded\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors face a competitive threat from the launch of biosimilars, including biosimilar infliximab and biosimilar etanercept, which provide cost-effective alternatives.\u00a0With the impending entry of additional\u00a0<abbr data-original-title=\"Janus activated kinase\" title=\"\">Jak<\/abbr>\u00a0inhibitors (AbbVie\u2019s upadacitinib, Galapagos\u2019s filgotinib) and biosimilars of several other\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>\u00a0and non-<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>\u00a0biologics, marketers are faced with fierce competition and increasing challenges to gain market uptake.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>What are key opinion leaders\u2019 perceptions of the advantages and disadvantages of these drugs? What factors influence the prescription of one\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitor over another?<\/li>\n<li>What are key opinion leaders\u2019 perceptions of the currently marketed non-<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitor biologics and novel oral kinase inhibitors, and where do these agents fit in their current treatment approach? Which emerging agents are likely to be most successful in targeting the\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-refractory patient segment and gaining uptake in the\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>\u00a0market?<\/li>\n<li>What will be the impact of the entry of additional novel oral therapies on the treatment algorithm for\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>? In which patient segments and lines of treatment will these oral therapies most likely be used? What is this drug class\u2019s market potential in\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>?<\/li>\n<li>How will the entry of biosimilars affect the market sales and patient share of currently marketed\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>\u00a0agents and the entry of emerging therapies?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a022\u00a0country-specific interviews with thought leaders.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Number of total, diagnosed, and drug-treated prevalent cases of\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>; number of diagnosed prevalent cases of\u00a0<abbr data-original-title=\"rheumatoid arthritis\" title=\"\">RA<\/abbr>\u00a0by severity.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Preregistered: 5\u00a0drugs; Phase III: 4 drugs; Phase II: 22\u00a0drugs; coverage of 10\u00a0select preclinical and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-390564","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390564\/revisions"}],"predecessor-version":[{"id":393688,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390564\/revisions\/393688"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}